Skip to main content

Table 2 Predictors of response to vaccine at five weeks in MPN patients

From: Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Variables

Univariate analysis

Responders (IgG > 15 AU/mL)

p (*)

Age

 < 72 years (n = 21)

19 (90.5%)

0.663

 > 72 years (n = 21)

17 (81%)

 

Gender

 M (n = 20)

17 (85%)

1

 F (n = 22)

19 (86.4%)

 

Body mass index (kg/sm2)

 < 25.5 (n = 20)

19 (95%)

0.187

 > 25.5 (n = 22)

17 (77.3%)

 

Lines of therapy

 1 (n = 31)

26 (83.9%)

1

 > 1 (n = 11)

10 (90.9%)

 

Lymphocyte count

 < 1600/µL (n = 21)

16 (76.2%)

0.184

 > 1600/µL (n = 21)

20 (95.2%)

 

Neutrophils count

 < 4980/µL (n = 21)

20 (95.2%)

0.184

 > 4980/µL (n = 21)

16 (76.2%)

 

Time from diagnosis to vaccination

 < 62 months (n = 21)

16 (76.2%)

0.184

 62 months (n = 21)

20 (95.2%)

 

Time from the start of ongoing therapy to vaccination

 < 37 months (n = 21)

18 (85.7%)

1

 > 37 months (n = 21)

18 (85.7%)

 

Diagnosis

 Myelofibrosis (n = 10)

6 (60%)

0.021

 Polycythemia vera/essential thrombocythemia (n = 32)

30 (93.8%)

 

Treatment

 Ruxolitinib (n = 8)

5 (62.5%)

0.072

 Hydroxycarbamide/anagrelide/interferon alpha (n = 34)

31 (91.2%)

 
  1. Bold value is statistically significant
  2. *p value has been calculated using Fisher’s exact test